oronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Varian

Author(s)

Fumagalli, Marcilio Jorge ^[1] ; Castro-Jorge, Luiza Antunes ^[1] ; de Souza, William Marciel ^[2] ; de Azevedo, Patrick Orestes ^[3] ; Hansen, Alana Witt ^[4] ; Gazzinelli, Ricardo Tostes ^[3] ; da Fonseca, Benedito Antonio Lopes ^[1] ; Spilki, Fernando Rosado ^[4] ; Figueiredo, Luiz Tadeu Moraes ^[1]

Affiliation

^[1] Univ Sao Paulo, Virol Res Ctr, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto, SP - Brazil

^[2] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Dept Microbiol & Immunol, Galveston, TX 77555 - USA

^[3] Univ Sao Paulo, Platform Translat Med Oswaldo Cruz Fdn, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto - Brazil

^[4] Feevale Univ Novo Hamburgo, Hlthy Sci Inst, Mol Microbiol Lab, BR-93525075 Novo Hamburgo - Brazil

• Document type: Journal article
• Source: IRUSES-BASE; v. 14, n. 2 FEB 2022.
• Web of Science Citations: 0

Abstract

The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals. (AU)

• FAPESP's process: 18/09383-3 - Study about Flavivirus epitopes with medical importance in Brazil and its antibodies
• Grantee: Marcilio Jorge Fumagalli
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 20/05527-0 - Bivalent intranasal vaccine using influenza virus expressing SARS-CoV-2 protein S (spike): protection mechanisms and lung injury
• Grantee: Ricardo Tostes Gazzinelli
• Support Opportunities: Regular Research Grants
• FAPESP's process: 19/26119-0 - Emerging and re-emerging viruses: biology, pathogenesis and prospection
• Grantee: Eurico de Arruda Neto
• Support Opportunities: Research Projects - Thematic Grants